

INFORMATION DISCLOSURE CITATION

APPLICATION NO. 10/523047

(Use several sheets if necessary)

APPLICANT

Lane, Roger Michael et al.

FILING DATE

August 06, 2003

Group

1634

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	2000/19985	04/13/00	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	1999/25363	05/27/99	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	FORETTE F. et al., "A phase II study in patients with alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®), European Journal of Neurology, vol. 6, (4), pp. 243-429, (1999)
AS	FARLOW, M.R. et al., "Differential qualitative responses to rivastigmine in APOE ε4 carriers and noncarriers", The Pharmacogenomics Journal, vol. 4, pp. 332-335 (2004)
AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.